SCHEMBL3264833

SCHEMBL3264833

COc1ccc(S(=O)(=O)N(CCOc2ccccc2)c2ccc(Cl)cc2Cc2c(F)cccc2F)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.44
NPSR1 Q6W5P4 1/20 0.43
HCRTR2 O43614 3/20 0.42
HCRTR1 O43613 2/20 0.42
POLB P06746 1/20 0.39
MCOLN3 Q8TDD5 1/20 0.39
MAPT P10636 3/20 0.38
HIF1A Q16665 2/20 0.38
EPAS1 Q99814 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TP53 P04637 1/20 0.37
KEAP1 Q14145 2/20 0.37
NFE2L2 Q16236 2/20 0.37
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
EP300 Q09472 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3252995 0.90 PKM (0.47) PKMNPSR1HCRTR2HCRTR1POLB
SCHEMBL3255521 0.88 PKM (0.48) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL3255886 0.88 PKM (0.48) PKMNPSR1HCRTR2HCRTR1POLB
SCHEMBL4871023 0.87 PKM (0.52) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL3251964 0.87 PKM (0.49) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL3243770 0.87 PKM (0.47) PKMNPSR1HCRTR2HCRTR1POLB
SCHEMBL3251551 0.87 HCRTR2 (0.49) PKMHCRTR2HCRTR1POLBMCOLN3
SCHEMBL4870970 0.86 PKM (0.48) PKMNPSR1HCRTR2HCRTR1POLB
SCHEMBL3252756 0.86 PKM (0.46) PKMNPSR1HCRTR2HCRTR1POLB
SCHEMBL8273307 0.86 HCRTR2 (0.51) PKMHCRTR2HCRTR1POLBMCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 PKM 2524/4885NPSR1 54/4885HCRTR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.